A Study of Multiple Doses of LY2922470 in Participants With Diabetes

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to determine the safety of LY2922470, taken as oral capsules, once or twice daily for approximately 28 days, in participants with diabetes. It also aims to determine how long the drug stays in the body and how it affects blood sugar levels. A screening appointment is required within 28 days before the start of the study and a follow up appointment is required approximately 14 days after the last study dose is taken.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3502970 in Participants With Type 2 Diabetes

NCT04426474

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes

NCT01606371

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes

NCT01606397

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study for Participants With Type 2 Diabetes Mellitus

NCT00871572

Diabetes Mellitus, Type 2

COMPLETED PHASE2

A Study of LY2922083 in Healthy Participants and Participants With Diabetes

NCT01748552

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally as capsules

LY2922470

Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days

Group Type EXPERIMENTAL

LY2922470

Intervention Type DRUG

Administered orally as capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Administered orally as capsules

Intervention Type DRUG

LY2922470

Administered orally as capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be a male, or a female who cannot become pregnant, and who has type 2 diabetes
* Have a glycated hemoglobin (HbA1c) value of greater than or equal to 6.5% and less than or equal to 11% at screening
* Do not have any change to their diabetes treatment (exercise with or without metformin) for at least 4 weeks prior to screening
* Have a screening body mass index (BMI) of 18.0 to 45.0 kilograms per square meter (kg/m\^2)
* Have blood pressure, pulse rate, blood and urine laboratory test results acceptable for the study

Exclusion Criteria

* Are currently participating in another clinical study or completed one in the last 30 days
* Have a history of significant heart, lung, liver, kidney, stomach or brain disease, or have any medical problems which may cause an increased risk during the study
* Have electrocardiogram (ECG) readings that are not suitable for the study
* Are infected with hepatitis B or hepatitis C
* Are infected with human immunodeficiency virus (HIV)
* Have donated blood equal to or more than 500 mL within 56 days before the first dose of drug or have donated plasma within 7 days before the first dose or provided any blood donation within the last month from screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No